FinscoFinsco

Ionis Pharmaceuticals (US.IONS)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.IONS · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion118.3%↑
ROE-47.1%↓
Cash Conversion-→
D/E Ratio3.67↓
Gross Margin98.9%→
US.IONS (Ionis Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   118.3%    ↑
ROE              -47.1%    ↓
Cash Conversion       -    →
D/E Ratio          3.67    ↓
Gross Margin      98.9%    →
Key Metrics
US.IONS (Ionis Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 118.3% ↑
ROE -47.1% ↓
Cash Conversion - →
D/E Ratio 3.67 ↓
Gross Margin 98.9% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies